蛋白酶激活受体2:对于女性癌症来说,这是一个有前途的治疗标
Himani Shah1, David P Fairlie1, Junxian Lim1
1Centre for Chemistry and Drug Discovery and ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.
The Journal of pharmacology and experimental therapeutics
|February 1, 2025
概括
蛋白酶激活受体2 (PAR2) 在女性癌症中过度表达,促进瘤生长和入侵. 向PAR2为开发新型癌症疗法和提高治疗疗效提供了一个有前途的战略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 在G蛋白合受体信号传递中.
背景情况:
- 女性的癌症如乳腺癌,子宫癌,卵巢癌,子宫内膜癌和子宫癌越来越普遍.
- 由于发病率和死亡率的上升,目前的治疗需要创新方法.
研究的目的:
- 研究女性癌症与蛋白酶激活受体2 (PAR2) 之间的关联.
- 评估PAR2作为妇科和乳腺癌的潜在治疗点.
主要方法:
- 来自公开可用的数据库的精选PAR2基因表达数据.
- 分析了瘤组织中的PAR2表达与患有各种女性癌症的患者的正常组织.
主要成果:
- 与正常组织相比,在乳腺,子宫,卵巢,子宫内膜和宫癌组织中观察到PAR2的显著过度表达.
- 过度表达PAR2与瘤的进展,迁移,入侵,血管新生和亡有关.
- PAR2的激活会触发下游的信号通路,这些通路与瘤发生有关.
结论:
- 在女性癌症中,PAR2是新治疗策略的有前途的分子标.
- 抑制PAR2可能会提高现有化疗的疗效,从而有可能减少毒性剂量.
- 进一步开发PAR2抗剂对于在联合癌症治疗中临床应用至关重要.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Internal Receptors
69.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.3K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Enzyme-linked Receptors
77.1K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.1K


